{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:58Z","timestamp":1776276418163,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-00263261"],"award-info":[{"award-number":["RS-2023-00263261"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virol.2026.110883","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:39:03Z","timestamp":1773851943000},"page":"110883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175\/mp7 challenge in interferon-receptor\u2013deficient mice"],"prefix":"10.1016","volume":"619","author":[{"given":"Yong-Ju","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Pyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.110883_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.14030","article-title":"Evolution and impact of hepatitis A epidemiology in Europe-systematic literature review of the last 20 years","volume":"32","author":"Andani","year":"2025","journal-title":"J. Viral Hepat."},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2026.110883_bib2","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/0264-410X(92)90576-6","article-title":"Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings","volume":"10","author":"Andr\u00e9","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110883_bib3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/ani14060846","article-title":"Animal research regulation: improving decision-making and adopting a transparent system to address concerns around approval rate of experiments","volume":"14","author":"Azilagbetor","year":"2024","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.virol.2026.110883_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2026.110883_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003579","article-title":"Immunization of knock-out \u03b1\/\u03b2 interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine","volume":"9","author":"Canakoglu","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/339683","article-title":"Hepatitis A virus infection in tamarins: experimental transmission via contaminated factor VIII concentrates","volume":"185","author":"Chudy","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2188\/jea.JE20130022","article-title":"Development, production, and postmarketing surveillance of hepatitis A vaccines in China","volume":"24","author":"Cui","year":"2014","journal-title":"J. Epidemiol."},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2026.110883_bib9","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/infdis\/171.Supplement_1.S40","article-title":"Efficacy of an inactivated hepatitis A vaccine in pre- and postexposure conditions in marmosets","volume":"171","author":"D'Hondt","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41579-023-00889-z","article-title":"Cell entry and release of quasi-enveloped human hepatitis viruses","volume":"21","author":"Das","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2026.110883_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2334-7-73","article-title":"Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study","volume":"7","author":"Dom\u00ednguez","year":"2007","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.puhe.2016.03.027","article-title":"Risk factors for hospitalisation and associated costs among patients with hepatitis A associated with imported pomegranate arils, United States, 2013","volume":"136","author":"Epson","year":"2016","journal-title":"Public Health"},{"key":"10.1016\/j.virol.2026.110883_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031740","article-title":"History of the discovery of hepatitis A virus","volume":"9","author":"Feinstone","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.virol.2026.110883_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.182.4116.1026","article-title":"Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness","volume":"182","author":"Feinstone","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.virol.2026.110883_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/bs.aivir.2020.08.004","article-title":"Quasi-enveloped hepatitis virus assembly and release","volume":"108","author":"Feng","year":"2020","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.virol.2026.110883_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-virology-031413-085359","article-title":"Naked viruses that aren't always naked: quasi-enveloped agents of acute hepatitis","volume":"1","author":"Feng","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.virol.2026.110883_bib16","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.1073\/pnas.1805268115","article-title":"Biological sex affects vaccine efficacy and protection against influenza in mice","volume":"115","author":"Fink","year":"2018","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2026.110883_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02121807","article-title":"Hepatitis A-virus in cell culture: I. Propagation of different hepatitis A-virus isolates in a fetal rhesus monkey kidney cell line (Frhk-4)","volume":"168","author":"Flehmig","year":"1980","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.virol.2026.110883_bib18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/v14081668","article-title":"Susceptibility of type I interferon receptor knock-out mice to heartland bandavirus (HRTV) infection and efficacy of favipiravir and ribavirin in the treatment of the mice infected with HRTV","volume":"14","author":"Fujii","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2026.110883_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/vaccines12020204","article-title":"The shifting epidemiology of hepatitis A in the world health organization western Pacific region","volume":"12","author":"Gloriani","year":"2024","journal-title":"Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.virol.2026.110883_bib20","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(05)80370-8","article-title":"Hepatitis and hepatitis A vaccine: a glimpse of history","volume":"18","author":"Hilleman","year":"1993","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110883_bib21","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.aaf8325","article-title":"MAVS-dependent host species range and pathogenicity of human hepatitis A virus","volume":"353","author":"Hirai-Yuki","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.virol.2026.110883_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01998-16","article-title":"Biliary secretion of quasi-enveloped human hepatitis A virus","volume":"7","author":"Hirai-Yuki","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.virol.2026.110883_bib23","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031674","article-title":"Murine models of hepatitis A virus infection","volume":"9","author":"Hirai-Yuki","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.virol.2026.110883_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110883_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.110883_bib26","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1099\/0022-1317-72-9-2167","article-title":"A recombinant vaccinia virus expressing hepatitis A virus structural polypeptides: characterization and demonstration of protective immunogenicity","volume":"72","author":"Karayiannis","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2026.110883_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/157.2.338","article-title":"Studies of prototype live hepatitis A virus vaccines in primate models","volume":"157","author":"Karron","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib28","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1016\/j.vaccine.2015.10.009","article-title":"Decreasing immunity to hepatitis A virus infection among US adults: findings from the national health and nutrition examination survey (NHANES), 1999\u20132012","volume":"33","author":"Klevens","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110883_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2026.110883_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cld.1014","article-title":"Histological grading and staging of chronic hepatitis","volume":"17","author":"Krishna","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.virol.2026.110883_bib31","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031815","article-title":"Nonhuman primate models of hepatitis A virus and hepatitis E virus infections","volume":"9","author":"Lanford","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"17","key":"10.1016\/j.virol.2026.110883_bib32","first-page":"32278","article-title":"Advance online publication. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention","volume":"S0168\u20138278","author":"Lemon","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110883_bib33","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1073\/pnas.1619519114","article-title":"Protein composition of the hepatitis A virus quasi-envelope","volume":"114","author":"McKnight","year":"2017","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2026.110883_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/vaccines8040780","article-title":"Universal single-dose vaccination against hepatitis A in children in a region of high endemicity","volume":"8","author":"Mikhailov","year":"2020","journal-title":"Vaccines."},{"key":"10.1016\/j.virol.2026.110883_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01395-25","article-title":"Advance online publication. Natural killer cells and IFN-\u03b3 protect against liver injury during HAV infection in mice","volume":"99","author":"Misumi","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.110883_bib36","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s12325-022-02070-z","article-title":"Therapeutic advances in viral hepatitis A-E","volume":"39","author":"Nagra","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.virol.2026.110883_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.virol.2026.110883_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0140-6736(93)91736-6","article-title":"Acute liver failure: redefining the syndromes","volume":"342","author":"O'Grady","year":"1993","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2026.110883_bib39","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/0264-410X(92)90557-Z","article-title":"Production, quality control and characterization of an inactivated hepatitis A vaccine","volume":"10","author":"Peetermans","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110883_bib40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3181\/00379727-172-41570","article-title":"Studies in chimpanzees of live, attenuated hepatitis A vaccine candidates","volume":"172","author":"Provost","year":"1983","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.virol.2026.110883_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jmv.1890190105","article-title":"An inactivated hepatitis A viral vaccine of cell culture origin","volume":"19","author":"Provost","year":"1986","journal-title":"J. Med. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2026.110883_bib42","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/0264-410X(92)90572-2","article-title":"Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees","volume":"10","author":"Purcell","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.110883_bib44","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1086\/340520","article-title":"Relative infectivity of hepatitis A virus by the oral and intravenous routes in 2 species of nonhuman primates","volume":"185","author":"Purcell","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2026.110883_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ilar.42.2.161","article-title":"Animal models of hepatitis A and E","volume":"42","author":"Purcell","year":"2001","journal-title":"ILAR J."},{"key":"10.1016\/j.virol.2026.110883_bib45","article-title":"Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate","volume":"7","author":"Qu","year":"2011","journal-title":"3CD. PLOS Pathog."},{"key":"10.1016\/j.virol.2026.110883_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43983","article-title":"Cellular entry and uncoating of naked and quasi-enveloped human hepatoviruses","volume":"8","author":"Rivera-Serrano","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.virol.2026.110883_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01496-22","article-title":"Macrophage depletion reactivates fecal virus shedding following resolution of acute hepatitis A in Ifnar1\u2212\/\u2212 mice","volume":"96","author":"Shiota","year":"2022","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2026.110883_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cld.1018","article-title":"The history of hepatitis A. Clin","volume":"16","author":"Shouval","year":"2020","journal-title":"Liver Dis."},{"key":"10.1016\/j.virol.2026.110883_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2022.09.013","article-title":"Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection","volume":"78","author":"Sun","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110883_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009960","article-title":"IRF3-mediated pathogenicity in a murine model of human hepatitis A","volume":"17","author":"Sun","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2026.110883_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/v13060998","article-title":"Bile goes viral","volume":"13","author":"Tenge","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2026.110883_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.30802\/AALAS-CM-20-000119","article-title":"Overview of nonhuman primate models of SARS-CoV-2 infection","volume":"71","author":"Trichel","year":"2021","journal-title":"Comp. Med."},{"key":"10.1016\/j.virol.2026.110883_bib53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/14760584.4.4.459","article-title":"Prevention of hepatitis A by Havrix: a review","volume":"4","author":"Van Herck","year":"2005","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.virol.2026.110883_bib54","first-page":"3","article-title":"Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential","volume":"39","author":"Wong","year":"2018","journal-title":"Zool. Res."},{"key":"10.1016\/j.virol.2026.110883_bib55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4161\/hv.27124","article-title":"Live attenuated hepatitis A vaccines developed in China","volume":"10","author":"Xu","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2026.110883_bib56","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1073\/pnas.0611506104","article-title":"Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor","volume":"104","author":"Yang","year":"2007","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2026.110883_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jmv.1890400106","article-title":"Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization","volume":"40","author":"Zaaijer","year":"1993","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virol.2026.110883_bib58","article-title":"Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Public Health"},{"key":"10.1016\/j.virol.2026.110883_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104702","article-title":"The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: vaccine efficacy studies","volume":"174","author":"Zivcec","year":"2020","journal-title":"Antivir. Res."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268222600098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004268222600098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:17:05Z","timestamp":1776273425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004268222600098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"alternative-id":["S004268222600098X"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110883","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175\/mp7 challenge in interferon-receptor\u2013deficient mice","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110883"}}